Top 30 Companies Shaping the Future of Cancer Treatment in APAC
The oncology landscape in Asia-Pacific is undergoing a profound transformation, driven by rapid advancements in Cell & Gene Therapy (CGT) and RNA-based therapeutics.
As the region continues to expand its clinical and manufacturing capabilities, APAC is no longer just a participant in global innovation it is emerging as a key engine for next-generation cancer therapies.
In recent years, modalities such as CAR-T, TCR-T, AAV-based gene therapies, mRNA cancer vaccines, and RNA interference (siRNA) have moved beyond early-stage research into robust clinical pipelines, with multiple programs advancing through Phase II and Phase III trials.
Notably, China, South Korea, Japan, and Australia have established themselves as critical hubs, contributing significantly to the growing number of oncology-focused clinical programs across the region.
This report presents a curated overview of the Top 30 APAC companies actively developing CGT and RNA therapeutics for oncology.
By focusing on companies with clinical-stage pipelines, this analysis provides a clear snapshot of where innovation is happening, which modalities are gaining traction, and how the competitive landscape is evolving across both hematologic and solid tumor indications.
Beyond highlighting individual companies, this report also reflects broader industry trends:
- The continued dominance of cell therapies (particularly CAR-T) in hematological malignancies
- The increasing shift towards solid tumor applications
- The rising momentum of RNA-based platforms, particularly in cancer vaccines and targeted gene silencing
As the CGT and RNA ecosystems mature, collaboration between biopharma companies, CDMOs, technology providers, and regulatory bodies will be critical in accelerating the path from clinical development to commercialisation.
We hope this report serves as a valuable resource for biopharma leaders, solution providers, investors, and industry stakeholders seeking to navigate and capitalise on the rapidly evolving oncology landscape in APAC.
CGT World Asia 2026 + RNA Therapeutics & Manufacturing Asia 2026 brings these communities together for cross-disciplinary learning, partnerships, and growth all in one place in Singapore.
APAC’s oncology advanced therapies market is evolving fast.
CGT and RNA companies listed here are advancing new ways to treat both solid and hematologic cancers, shaping tomorrow’s therapies today.
CGT World Asia + RNA Asia 2026 provides a unique platform to connect with these innovators, explore collaborations, and stay ahead of technology and market trends.
This is where the APAC advanced therapeutics ecosystem meets so you can learn, connect, and grow together.
Join Cell & Gene Therapy World Asia 2026 & RNA Therapeutics & Manufacturing Asia 2026
Share With Your Network
